Global Neurological Disorder Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Technology;

Imaging (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine Imaging, Positron Emission Tomography (PET), Single-photon Emission Computed Tomography (SPECT), Near Infrared Spectroscopic Imaging (NIRS), Electroencephalography (EEG), and Magnetoencephalography (MEG)) and In Vitro Diagnostics (Biomarker, Biopsy, and Others).

By Disease Indication;

Genetic Neurological Disorders (Alzheimer's Disease (AD), Parkinsons Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Others), Immunological Neurological Disorders (Multiple Sclerosis and Others), Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn119752626 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Neurological Disorder Diagnostics Market (USD Million), 2021 - 2031

In the year 2024, the Global Neurological Disorder Diagnostics Market was valued at USD 16,995.47 million. The size of this market is expected to increase to USD 28,068.05 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.

The Global Neurological Disorder Diagnostics Market encompasses a wide array of diagnostic techniques, tools, and technologies aimed at identifying and managing various neurological conditions affecting the central and peripheral nervous systems. With neurological disorders posing significant challenges to global healthcare systems due to their complex nature and diverse manifestations, accurate and timely diagnosis is paramount for effective treatment and patient care. The introduction of innovative diagnostic modalities and advancements in neuroimaging, biomarker analysis, and genetic testing have revolutionized the field, driving the growth and evolution of the neurological disorder diagnostics market.

Neurological disorders encompass a broad spectrum of conditions, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, as well as neuropsychiatric disorders like depression, anxiety, and schizophrenia. These disorders present unique diagnostic challenges due to their heterogeneous nature, variable symptomatology, and overlapping clinical features. Healthcare providers rely on a combination of clinical assessments, imaging studies, laboratory tests, and genetic analyses to accurately diagnose and characterize neurological conditions, highlighting the multidisciplinary approach required in neurological disorder diagnostics.

The global neurological disorder diagnostics market is characterized by continuous innovation and technological advancements aimed at improving diagnostic accuracy, efficiency, and patient outcomes. Neuroimaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) play a crucial role in visualizing structural and functional abnormalities in the brain and spinal cord, aiding in the diagnosis and monitoring of neurological disorders. Additionally, the development of novel biomarkers and genetic testing methodologies enables early detection, prognostication, and personalized treatment approaches, driving the demand for advanced diagnostic tools and platforms.

The increasing prevalence of neurological disorders globally, coupled with the growing aging population and rising healthcare expenditures, fuels the demand for neurological disorder diagnostics. With neurological disorders posing significant socioeconomic burdens due to their long-term disability and healthcare costs, early and accurate diagnosis is essential for optimizing patient outcomes, reducing disease progression, and minimizing healthcare expenditures. The integration of artificial intelligence (AI) and machine learning algorithms into neurological disorder diagnostics holds immense promise for enhancing diagnostic accuracy, streamlining workflows, and facilitating precision medicine approaches tailored to individual patient profiles.

In conclusion, the global neurological disorder diagnostics market is characterized by innovation, technological advancements, and growing demand driven by the increasing prevalence of neurological disorders and the need for accurate and timely diagnosis. As healthcare systems strive to address the diagnostic challenges posed by neurological conditions, the market continues to evolve, offering opportunities for stakeholders to leverage emerging technologies and diagnostic modalities to improve patient care and outcomes in the field of neurology.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Technology
    2. Market Snapshot, By Disease Indication
    3. Market Snapshot, By Region
  4. Global Neurological Disorder Diagnostics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing neurological disorder prevalence
        2. Aging population
        3. Diagnostic technology advancements
        4. Growing awareness of early detection importance
      2. Restraints
        1. Limited accessibility in some regions
        2. Regulatory barriers
        3. Shortage of skilled professionals
        4. Biomarker standardization challenges
      3. Opportunities
        1. Neuroimaging, biomarker tech innovation
        2. Point-of-care diagnostics growth
        3. Wearable device adoption
        4. Screening, early detection programs
        5. Neurodiagnostics startup investments
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Neurological Disorder Diagnostics Market, By Technology, 2021 - 2031 (USD Million)
      1. Imaging
        1. Computed Tomography (CT)
        2. Magnetic Resonance Imaging (MRI)
        3. Nuclear Medicine Imaging
        4. Positron Emission Tomography (PET)
        5. Single-photon Emission Computed Tomography (SPECT)
        6. Near Infrared Spectroscopic Imaging (NIRS)
        7. Electroencephalography (EEG)
        8. Magnetoencephalography (MEG)
      2. In Vitro Diagnostics
        1. Biomarker
        2. Biopsy
        3. Others
    2. Global Neurological Disorder Diagnostics Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Genetic Neurological Disorders
        1. Alzheimer’s Disease (AD)
        2. Parkinson’s Disease (PD)
        3. Amyotrophic Lateral Sclerosis (ALS)
        4. Huntington's Disease (HD)
        5. Others
      2. Immunological Neurological Disorders
        1. Multiple Sclerosis
        2. Others
      3. Paraneoplastic Syndrome
      4. Paraproteinemic Neuropathies
      5. Others
    3. Global Neurological Disorder Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Siemens Healthineers
      2. GE Healthcare
      3. Philips Healthcare
      4. Hitachi Medical Systems
      5. Fujifilm Holdings Corporation
      6. Thermo Fisher Scientific Inc.
      7. Abbott Laboratories
      8. Bio-Rad Laboratories, Inc.
      9. PerkinElmer, Inc.
      10. F. Hoffmann-La Roche Ltd.
      11. Agilent Technologies, Inc.
      12. Bruker Corporation
      13. Hologic, Inc.
      14. QIAGEN N.V.
      15. Becton, Dickinson and Company
  7. Analyst Views
  8. Future Outlook of the Market